Fabrice Yves Ndjana Lessomo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Fabrice Yves Ndjana Lessomo has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
Chishimba Mukuka
Mansa Hospital, Mansa, Zambia
1 shared publicationOscar Onayi Mandizadza
Zhejiang Chinese Medical University, Hangzhou, China
1 shared publication- Zhiquan Wang
Cardiovascular Internal Medicine Department, Zhongnan Hospital of Wuhan University, Wuhan, China
1 shared publication
Latest Publications
- Open Access
- 8 November 2023
- Published by Springer Nature in European Journal of Medical Research
- Vol. 28 (1) , 1-14
A comprehensive review on immune checkpoint inhibitors induced cardiotoxicity characteristics and associated factors
Newly approved cancer drugs called ICIs have shown remarkable success in improving patient survival rates, but they also have the potential for inflammatory and immune-related side effects, including those affecting the cardiovascular system. Research has been conducted to understand the development of these toxicities and identify risk factors. This review focuses on the characteristics of ICI-induced cardiotoxicity and discusses the reported risk factors. It is important for cardio-oncologists to understand the basic concepts of these drugs to better understand how cardiotoxicities occur. It might be hard to find reports, where all patients treated with ICIs had developed cardiac toxicity, because there could be other existing and variable factors that influence the likelihood or risk of developing cardiotoxicity during treatment. Various clinical parameters have been explored as potential risk factors, and further investigation is needed through large-scale studies.
- 8 November 2023
- Published by Springer Nature in European Journal of Medical Research
- Vol. 28 (1) , 1-14
Open AccessA comprehensive review on immune checkpoint inhibitors induced cardiotoxicity characteristics and associated factors
Newly approved cancer drugs called ICIs have shown remarkable success in improving patient survival rates, but they also have the potential for inflammatory and immune-related side effects, including those affecting the cardiovascular system. Research has been conducted to understand the development of these toxicities and identify risk factors. This review focuses on the characteristics of ICI-induced cardiotoxicity and discusses the reported risk factors. It is important for cardio-oncologists to understand the basic concepts of these drugs to better understand how cardiotoxicities occur. It might be hard to find reports, where all patients treated with ICIs had developed cardiac toxicity, because there could be other existing and variable factors that influence the likelihood or risk of developing cardiotoxicity during treatment. Various clinical parameters have been explored as potential risk factors, and further investigation is needed through large-scale studies.